AI Generated Image
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
The New York Times • • business
Key Points:
- Novartis announced that its experimental drug pelacarsen, aimed at preventing heart attacks, strokes, and cardiovascular deaths, has failed in clinical trials, shocking the cardiology community.
- Pelacarsen targets lipoprotein (a), a protein strongly linked to heart disease risk, and had been seen as a promising breakthrough after previous studies suggested lowering Lp(a) would reduce heart disease.
- Cardiologists had high hopes that Lp(a)-lowering drugs like pelacarsen would become as important as statins in preventing heart attacks, especially in patients who maintain healthy lifestyles but remain at risk.
- The failure of pelacarsen is considered a significant setback in cardiovascular medicine, with experts expressing deep disappointment and surprise given the extensive promotion and investment by Novartis.
